EVs derived from these modified cells were loaded with the tumor suppressor gene let‐7a and systemically administered into epidermal growth factor‐expressing breast cancer mice.[186] Upon administration, GE11‐engineered EVs showed, compared with unmodified EVs, a pronounced increase in tumor accumulation and exhibited an antitumor effect mediated by let‐7a.[186] Although accumulation of EVs in other organs was not quantified, the depicted results showed a substantial accumulation of both targeted and untargeted EVs in the liver. The gene discussed is EGF; the disease is neoplasm.